KHẢO SÁT BƯỚC ĐẦU VỀ MỨC ĐỘ BIỂU HIỆN CỦA PD-L1 TRÊN BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ

Abstract

Background: Programmed death ligand 1 (PD-L1) expression is a predictive biomarker of the success of PD-1/PD-L1 inhibitor therapy for patients with advanced nonsmall cell lung cancer (NSCLC) but its role as a prognostic marker in Vietnam remains unclear. Therefore, our study aims to achieve two objectives: 1. To describe PD-L1 expression in non-small cell lung cancer; 2. To determine the relationship between PD-L1 expression and clinical characteristics. Materials and methods: We analysed 28 formalinfixed paraffin-embedded tissue samples from non-small cell lung cancer patients. These samples were stained using the PD-L1 IHC 22C3 pharmDx kit from Agilent. Results and conclusions: Among the 28 patients, 46.4% of patients is negative for PD-L1. Expression of PD-L1 scores of Tumor Proportion scores (TPS) of ≥ 50% and 1-49% were observed in 35.7% and 17.9% respectively. PD-L1 positivity tended to be higher in patients with squamous cell carcinoma and at advanced stages. There was no relationship between PDL1 expression and age or gender. These preliminary findings provide the basic for further further in-depth studies in identify the role PD-L1 in non-small cell lung cancer patients.